Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer

Laboratory Investigation

Volumn 74, Issue 1, 1996, Pages 168-177

  Nielsen, Boye Schnack ^a,b,c   Sehested, Maxwell ^b   Timshel, Susanne ^b   Pyke, Charles ^a   Danø, Keld ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AMAGER HOSPITAL   (Denmark)

^c FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; UROKINASE;

ARTICLE; BREAST CANCER; CANCER INVASION; CELLULAR DISTRIBUTION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADENOFIBROMA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; HUMANS; IN SITU HYBRIDIZATION; PLASMINOGEN ACTIVATORS; RNA, MESSENGER; STROMAL CELLS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030061754     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Ahmed A (1990). The myofibroblast in breast disease. In: Rosen PP and Fechner RE, editors. Pathology annual, part 2, vol 25. East Norwalk, CT: Appleton and Lange, 237-286.
2. Andreasen PA, Georg B, Lund LR, Riccio A, and Stacey SN (1990). Plasminogen activator inhibitors: Hormonally regulated serpins. Mol Cell Endocrinol 68:1-19.
3. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, and Chambon P (1990). A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699-704.
4. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, and Smith HS (1994). The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54:861-866.
5. Blasi F, Vassalli JD, and Danø K (1987). Urokinase-type plasminogen activator: Proenzyme, receptor, and inhibitors. J Cell Biol 104:801-804.
6. Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, and Salvatore M (1994). Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 54:5445-5454.
7. Costantini V, Zacharski LR, Memoli VA, Kudryk BJ, Rousseau SM, and Stump DC (1991). Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Cancer Res 51:354-358.
8. Crowley CW, Cohen RL, Lucas BK, Uu G, and Shuman MA (1993). Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90:5021-5025.
9. Cubellis MV, Wun TC, and Blasi F (1990). Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9:1079-1085.
10. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, and Skriver L (1985). Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44:139-266.
11. Danø K, Grøndahl-Hansen J, Eriksen J, Schnack Nielsen B, Rømer J, and Pyke C (1993). The receptor for urokinase plasminogen activator: Stromal cell involvement in extracellular proteolysis during cancer invasion. In: Barret AJ and Bond J, editors. Proteolysis and protein turnover. London: Portland Press, 239-245.
12. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, and Pyke C (1994). The urokinase receptor: Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8:189-203.
13. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, and Balkwill FR (1993). Activity of type IV collagenases in benign and in malignant breast disease. Br J Cancer 67:1126-1131.
14. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, and Esposito G (1993). Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels. Cancer Res 53:3198-3206.
15. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, and Andreasen P (1990). Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827-6829.
16. Ellis V, Pyke C, Eriksen J, Solberg H, and Danø K (1992). The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 667:13-31.
17. Falini B, Flenghi L, Pileri S, Gambacorta M, Bigerna B, Durkop H, Eitelbach F, Thiele J, Pacini R, Cavaliere A, Martelli M, Cardarelli N, Sabattinin E, Poggi S, and Stein H (1993). PG-M 1: A new monoclonal antibody directed against a fixative resistant epitope on the macrophage-restricted form of the CD68 molecule. Am J Pathol 142:1359-1372.
18. Gray ST, Yun K, Motoori T, and Kuys YM (1993). Interstitial collagenase gene expression in colonic neoplasia. Am J Pathol 143:663-671.
19. Grøndahl-Hansen J, Ralfkiær E, Kirkeby LT, Kristensen P, Lund LR, and Danø K (1991). Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138:111-117.
20. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, and Blichert-Toft M (1993). High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521.
21. Grøndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Brünner N, and Foekens JA (1995). Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1:1079-1087.
22. Guelstein VI, Tchypysheva TA, Ermilova VD, Litvinova LV, Troyanovsky SM, and Bannikov GA (1988). Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int J Cancer 42:147-153.
23. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewski K, and Harris AL (1992). Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastasis and survival in breast cancer. Lancet 340:1120-1124.
24. Jankun J, Merrick HW, and Goldblatt PJ (1993). Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 53:135-144.
25. Jänicke F, Schmitt M, and Graeff H (1991). Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17:303-312.
26. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N, and Terao T (1994). Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontanous metastasis model. Int J Cancer 57:727-733.
27. Kook YH, Adamski J, Zelent A, and Ossowski L (1994). The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13:3983-3991.
28. Liotta LA, Steeg PS, and Stetler-Stevenson WG (1991). Cancer, metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336.
29. Majno G, Gabbiani G, Hirschel BJ, Ryan GB, and Statkov PR (1971). Contraction of granulation tissue in vitro: Similarity to smooth muscle. Science 173:548-550.
30. Matrisian LM (1990). Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121-125.
31. Mignatti P and Rifkin DB (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195.
32. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, and Comoglio PM (1995), Biological activation of pro-HGF (Hepatocyte Growth Factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270:603-611.
33. Nykjasr A, Petersen CM, Møller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thøgersen HC, Munch M, Andreasen P, and Gliemann J (1992). Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type 1 complex: Evidence that the alpha2-macroglobulin receptor mediates cellular degradation of urokinase receptor bound complexes. J Biol Chem 267: 14543-14546.
34. Odekon LE, Blasi F, and Rifkin DB (1994). Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol 158:398-407.
35. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, and Basset P (1995). Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92:2730-2734.
36. Ossowski L (1988). In vivo invasion of modified chorioallantoic membrane by tumor cells: The role of cell surface-bound urokinase. J Cell Biol 107:2437-2445.
37. Ossowski L, Clunie G, Masucci M, and Blasi F (1991). In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion. J Cell Biol 115:1107-1112.
38. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, Danø K, and Grøndahl-Hansen J (1994). Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54:4671-4675.
39. Petersen LC, Lund LR, Nielsen LS, Danø K, and Skriver L (1988). One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 263:11189-11195.
40. Poulsom R, Pignatelli M, Stetler Stevenson WG, Liotta LA, Wright PA, Jeffrey RE, Longcroft JM, Rogers L, and Stamp GWH (1992). Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141:389-396.
41. Poulsom R, Hanby AM, Pignatelli M, Jeffery RE, Longcroft JM, Rogers L, and Stamp GW (1993). Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 46:429-436.
42. Pyke C, Kristensen P, Ralfkiær E, Grøndahl-Hansen J, Eriksen J, Blasi F, and Danø K (1991a). Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138:1059-1067.
43. Pyke C, Kristensen P, Ralfkiær E, Eriksen J, and Danø K (1991b). The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 51:4067-4071.
44. Pyke C, Ralfkiær E, Tryggvason K, and Danø K (1993a). Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142:359-365.
45. Pyke C, Græm N, Ralfkiær E, Rønne E, Høyer-Hansen G, Brünner N, and Danø K (1993b). Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53:1911-1915.
46. Pyke C, Ralfkiær E, Rønne E, Høyer-Hansen G, Kirkeby L, and Danø K (1994). Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24:131-138.
47. Roldan AL, Cubellis MV, Masucci M, Behrendt N, Lund LR, Danø K, Appella E, and Blasi F (1990). Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proeolysis. EMBO J 9:467-474.
48. Rouyer N, Wolf C, Chenard MP, Rio MC, Chambon P, Bellocq JP, and Basset P (1995). Stromelysin-3 gene expression in human cancer: An overview. Invasion Metastasis 14:269-275.
49. Rømer J, Lund LR, Eriksen J, Ralfkiær E, Zeheb R, Gelehrter TD, Danø K, and Kristensen P (1991). Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 97:803-811.
50. Rømer J, Lund LR, Eriksen J, Pyke C, Kristensen P, and Danø K (1994). The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol 102:519-522.
51. Rønnov-Jessen L, Van Deurs B, Nielsen M, and Petersen OW (1992). Identification, paracrine generation, and possible function of human breast carcinoma myofibroblasts in culture. In Vitro Cell Dev Biol 28A:273-283.
52. Rønnov-Jessen L and Petersen OW (1993). Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts: Implications for myofibroblast generation in breast neoplasia. Lab Invest 68:696-707.
53. Rønnov-Jessen L, Petersen OW, Koteliansky VE, and Bissel M (1995). The origin of the myofibroblasts in breast cancer: Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 95:859-873.
54. Sappino AP, Skalli O, Jackson B, Schürch W, and Gabbiani G (1988). Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer 41:707-712.
55. Sappino AP, Schürch W, and Gabbiani G (1990). Differentiation repertoire of fibroblastic cells: Expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 63:144-161.
56. Sappino AP, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH, and Vassalli JD (1991). Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88:1073-1079.
57. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillesen D, and Gabbiani G (1986). A monoclonal antibody against alpha-smooth muscle actin: A new probe for smooth muscle differentiation. J Cell Biol 103:2787-2796.
58. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, and Takada A (1991). Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: Possible roles in tumor progression and metastasis. Thromb Res 63:59-71.
59. Tramu G, Pillez A, and Leonardelli J (1978). An efficient method of antibody elution for the successive or simultaneous localization of two antigens by immuhistochemistry. J Histochem Cytochem 26:322.
60. Vassalli J, Baccino D, and Belin D (1985). A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100:86-92.
61. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, and Basset P (1993). Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90:1843-1847.